TheraRadar
← Back
Data updated: Jul 17, 2026

SmartPractice Denmark ApS

Biotech
Pharmaceuticals

SmartPractice Denmark ApS is a biotechnology company with 2 FDA-approved products.

1997
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Biologics

SmartPractice Denmark ApS's Key Drugs

SmartPractice Denmark ApS's core commercial portfolio centers on hudquzco rubber panel,rubber panel t.r.u.e. test — its most strategically important drugs approved in the last 15 years.

SmartPractice Denmark ApS's Recent FDA Approvals

New NDA/BLA approvals for SmartPractice Denmark ApS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SmartPractice Denmark ApS's Therapeutic Areas

Disease areas where SmartPractice Denmark ApS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

SmartPractice Denmark ApS Pipeline Snapshot

Active clinical trials for SmartPractice Denmark ApS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • hudquzco rubber panel,rubber panel t.r.u.e. test leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling